RE:RE:ONCY has just added to the profit margin of Cantor FitzgeralThrows open the door to the Accelerated Approval pathway for ONCY's pelareorep in combination with paclitaxel for the treatment of HR+/HER2- metastatic Breast Cancer used in 2 different scenarios- (1) either prior to (in ADC intolerant) which was originally planned before ADC therapy, or (2) following ADC therapy (in ADC failure).